Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

|Videos|June 26, 2022

Key Pearls on Innovative Treatments in PsA

Author(s)Kaitlyn Bader, Associate Editor

Arthur Kavanaugh, MD, a professor of medicine and director of the Center for Innovative Therapy (CIT) at UC San Diego in California, gives his thoughts on the treatments for psoriatic arthritis, the comorbidities that have to be considered, and more.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Guselkumab's CD64 Binding Offers Targeted IL-23 Inhibition in PsA

ByPhilip J. Mease, MD,Kaitlyn Bader, Assistant Managing Editor

July 10th 2026

5 Dermatology Approvals to Know from the First Half of 2026

ByPatrick Campbell

July 10th 2026

APEX Data Reinforce Case For Early PsA Treatment With Guselkumab

ByPhilip J. Mease, MD,Kaitlyn Bader, Assistant Managing Editor

July 8th 2026

Why Do Some Psoriasis Patients Respond Differently to Biologics? New Study Offers Clues

ByShannon Heaning, Content Associate

July 7th 2026

Smoking Associated with Increased Nail Psoriasis Severity, Case-Control Study Finds

ByMarie Bosslett, Assistant Editor

July 7th 2026

Latest CME

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis

New Review Confirms How Nonmedicated Skin Care Vehicles Drive Clinical Improvement

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

Social Media Mythbusters: The Summer Skin Care "Shutdown"

AI-Assisted Imaging Tracks Success of Low-Fluence QSRL Laser for Melasma